Group One Trading’s Mersana Therapeutics MRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-20
Closed -$148 8858
2025
Q2
$148 Hold
20
﹤0.01% 7764
2025
Q1
$172 Sell
20
-2,556
-99% -$39.4K ﹤0.01% 7383
2024
Q4
$92.1K Sell
2,576
-48
-2% -$2.48K ﹤0.01% 4594
2024
Q3
$124K Sell
2,624
-36
-1% -$1.59K ﹤0.01% 4003
2024
Q2
$134K Buy
2,660
+2,628
+8,213% +$190K ﹤0.01% 3722
2024
Q1
$3.58K Sell
32
-48
-60% -$4.77K ﹤0.01% 6316
2023
Q4
$4.64K Sell
80
-380
-83% -$15.3K ﹤0.01% 6542
2023
Q3
$14.6K Sell
460
-3,648
-89% -$173K ﹤0.01% 6116
2023
Q2
$338K Buy
4,108
+3,228
+367% +$472K ﹤0.01% 3416
2023
Q1
$90.4K Buy
+880
New +$124K ﹤0.01% 4385
2022
Q4
Sell
-36
Closed -$6K 7788
2022
Q3
$6K Sell
36
-52
-59% -$8.45K ﹤0.01% 6755
2022
Q2
$10K Sell
88
-644
-88% -$60.6K ﹤0.01% 6759
2022
Q1
$73K Buy
732
+88
+14% +$10.3K ﹤0.01% 5795
2021
Q4
$100K Buy
+644
New +$125K ﹤0.01% 5726
2021
Q3
Sell
-88
Closed -$30K 8547
2021
Q2
$30K Sell
88
-400
-82% -$151K ﹤0.01% 6956
2021
Q1
$197K Buy
488
+88
+22% +$42.7K ﹤0.01% 5045
2020
Q4
$266K Buy
400
+360
+900% +$200K ﹤0.01% 3844
2020
Q3
$19K Sell
40
-488
-92% -$247K ﹤0.01% 5155
2020
Q2
$309K Buy
+528
New +$180K ﹤0.01% 3016

Other funds holding MRSN

Group One Trading's MRSN Position: Q1 2026 in Review

Group One Trading sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 1,073 shares — an estimated $31K sold.

Group One Trading first reported a position in MRSN in Q4 2020 and held it in 18 quarters. The position peaked at $527K in Q2 2023. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

  • Group One Trading reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 1,073 Mersana Therapeutics shares in Q1 2026, an estimated $31K.
  • Group One Trading first reported a position in Mersana Therapeutics in Q4 2020 and held it in 18 quarters.
  • Group One Trading's Mersana Therapeutics position peaked at $527K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.